CSER Phase 2 Provider Return of Results Follow-up #1 Survey is administered 0-6 weeks post-return of results to providers of research participants that were returned positive, negative, VUS, and secondary findings. It assesses provider experience with genetics, confidence in patient communication and care management, perceived utility of genomic test result for the patient's care, demographic information, and provider recommendations based on the genetic test result.

CSER Phase 2 Provider Return of Results Follow-up #2 Survey is administered at 5-7 months post-return of results, regardless of whether the provider has completed the CSER Phase 2 Provider Return of Results Follow-up #1 Survey. The Follow-up #2 Survey captures provider healthcare actions (screenings, procedures, drugs, and referrals) and recommendations.

A pre- and post-test questionnaire that measures changes in the knowledge and attitudes of physicians who have been administered pharmacogenetic testing is available in the supporting information section of the linked publication in both English and Korean. The survey includes items for demographic information, clinical history, attitudes towards adverse drug reactions, experience with clinical genomics, attitudes toward and experience with pharmacogenomics, price expectations for pharmacogenomics testing, and interpretation of the value of the pharmacogenomics report.